Quick facts
- Class
- GHRH(1-29) analog
- Former brand
- Geref (manufacturing discontinued)
- Studied for
- GH secretion; popularly for recovery/anti-aging
- Approval
- Previously approved; now compounded, not a standard FDA product
- Class
- GHRH analog / GHRH(1-29)
- Approval
- Formerly FDA-approved (Geref, discontinued); now compounded
- Half-life
- Short (roughly 10-20 minutes)
- Anti-doping
- Prohibited at all times (WADA category S2)
Key takeaways
- Sermorelin is a GHRH(1-29) peptide — the shortest fully active fragment of growth hormone-releasing hormone — that stimulates the pituitary to release GH.
- It was formerly FDA-approved under the brand name Geref for diagnostic and therapeutic use, but the branded product was later discontinued.
- It is now typically available through compounding pharmacies rather than as a mass-marketed approved product.
- Because it stimulates the body's own GH production, it preserves the natural pulsatile pattern of GH release.
- It is prohibited in sport at all times under WADA rules.
Overview
Sermorelin is a peptide corresponding to the first 29 amino acids of growth hormone-releasing hormone, the segment responsible for GHRH's biological activity. It stimulates the pituitary gland to release the body's own growth hormone and was historically used as a diagnostic and therapeutic agent.
It was previously approved by the FDA and sold under the brand name Geref, but that approved product was discontinued, so sermorelin is no longer marketed as a standard FDA-approved drug in its original form. Today it is most often encountered as a compounded preparation, prescribed through compounding pharmacies for purposes such as growth hormone support and anti-aging, an area where promotional claims often exceed the evidence.
This history gives sermorelin an unusual status: a molecule with a legitimate pharmaceutical past whose current availability runs largely through compounding rather than conventional approval. Understanding that distinction is important for interpreting both its credibility and the claims made about it.
How it works
Sermorelin acts on GHRH receptors in the anterior pituitary, prompting the gland to synthesize and release growth hormone in a pulsatile manner. Because it stimulates the body's own production rather than supplying growth hormone directly, it works upstream and depends on a functioning pituitary to produce an effect.
The released growth hormone subsequently drives production of IGF-1, the downstream mediator of many growth hormone effects. In principle, this indirect approach preserves more of the body's natural regulatory feedback than injecting growth hormone itself, since the pituitary can still modulate its output.
This mechanism is the basis for sermorelin's historical use in assessing pituitary function and for its contemporary marketing as a way to encourage more youthful growth hormone activity. However, the existence of a plausible mechanism does not by itself establish that long-term sermorelin use produces meaningful clinical benefits in healthy adults, a point often glossed over in promotional material.
Research & evidence
Sermorelin has an established record in the assessment and stimulation of growth hormone secretion, including historical use in evaluating growth hormone deficiency, particularly in pediatric contexts. In that diagnostic and therapeutic role, its ability to provoke growth hormone release was well documented.
The contemporary use of compounded sermorelin for anti-aging, body composition, sleep, and general wellness in adults is far less rigorously supported. Much of the enthusiasm rests on the underlying logic of raising growth hormone rather than on large, controlled trials demonstrating durable clinical benefits for these specific purposes.
As a result, while sermorelin's basic pharmacology is well understood, the evidence for many popularly marketed benefits in healthy adults is limited. Claims should be weighed against this gap, and the molecule is best viewed as a pharmacologically active GHRH analog whose modern wellness applications are not strongly validated by high-quality outcome data.
Safety & legal status
Reported side effects of sermorelin include injection-site reactions, flushing, headache, and other effects associated with growth hormone stimulation. Because raising growth hormone and IGF-1 activity has systemic consequences, appropriate medical oversight, screening, and monitoring are important, and this guide does not provide dosing details.
Legally, the original branded sermorelin product was discontinued, and current availability is largely through compounding pharmacies operating under prescription. Compounded products are not subject to the same approval process as standard drugs, and quality can vary, so the source and oversight matter considerably.
In competitive sport, sermorelin is prohibited. As a GHRH analog that stimulates growth hormone release, it falls under the World Anti-Doping Agency's banned substances, and athletes subject to testing should not use it. Anyone considering sermorelin should do so only under qualified medical supervision and with realistic expectations.
Frequently asked questions
What is sermorelin?
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone, the active portion of GHRH. It stimulates the pituitary gland to secrete growth hormone.
Was sermorelin ever an approved drug?
Yes. Sermorelin was previously FDA-approved and marketed as Geref for uses including assessment of pituitary function and treatment of growth hormone deficiency, but the branded product was subsequently discontinued.
How is sermorelin obtained now?
Following discontinuation of the branded product, sermorelin is generally prepared by compounding pharmacies rather than sold as a standard commercial drug. Availability varies by country and regulation.
How does sermorelin differ from injecting growth hormone?
Sermorelin stimulates the pituitary to make and release its own GH in a natural pulsatile manner, whereas injected GH supplies the hormone directly. The pituitary response to sermorelin is also subject to the body's normal feedback controls.
Is sermorelin allowed in competitive sport?
No. As a GHRH analog and growth hormone secretagogue, sermorelin is prohibited at all times under the World Anti-Doping Agency's Prohibited List.
References
Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006. Peer-reviewed study
- Kerrigan JR, Martha PM Jr, Blizzard RM, et al. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. J Clin Endocrinol Metab. 1994. Peer-reviewed study
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. Peer-reviewed study
- Chang Y, Huang R, Zhai Y, et al. A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med. 2021. Peer-reviewed study